DOCSLIB.ORG

Covid-19 Thesaurus Covid-19 Thesaurus Version 1.2 (Last Updated: 2021-01-07)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Covid-19 Thesaurus Covid-19 Thesaurus Version 1.2 (Last Updated: 2021-01-07) - Institute for scientific and technical information - Covid-19 Thesaurus Covid-19 Thesaurus Version 1.2 (Last updated: 2021-01-07) This resource contains 1203 terminological entries. This bilingual thesaurus (French-English), developed at Inist-CNRS, covers the concepts from the emerging COVID-19 outbreak which reminds the past SARS coronavirus outbreak and Middle- East coronavirus outbreak. This thesaurus is based on the vocabulary used in scientific publications for SARS-CoV-2 and other coronaviruses, like SARS-CoV and MERS-CoV. It provides a support to explore the coronavirus infectious diseases . A French version of the thesaurus is also available. The thesaurus is browsable online on the terminological portal Loterre: https://www.loterre.fr Legend • Syn: Synonym. • → : Corresponding Preferred Term. • FR: French Preferred Term. • NT: Narrower Term. • BT: Broader Term. • RT: Related Term. • URI: Concept's URI (link to the online view). This resource is licensed under a Creative Commons Attribution 4.0 International license: TABLE OF CONTENTS Alphabetical Index 4 Terminological Entries 5 List of entries 174 Tree 201 Alphabetical Index from 2002 to 2019 p. 8 -8 from 3 LNP-mRNAs to 3 LNP-mRNAs p. 9 -9 from 501Y.V2 to 501Y.V2 p. 10 -10 from A222V mutation to azithromycin p. 16 -24 from B lymphocyte to Butantan Institute p. 28 -31 from C reactive protein to cytotoxic T lymphocyte p. 38 -48 from D-dimer to dyspnea p. 49 -53 from E protein to extracorporeal membrane oxygenation p. 55 -59 from facilitating antibody to fusion peptide p. 62 -64 from G clade to GX-19 p. 67 -70 from haemophagocytic lymphohistiocytosis to hypokalemia p. 75 -78 from IFITM protein to ivermectin p. 87 -92 from JAK-STAT to Johnson & Johnson p. 93 -94 from K417N mutation to kinase p. 95 -95 from L clade to lymphopaenia p. 96 -99 from M protein to myocarditis p. 108 -108 from N protein to Nyctereutes procyonoides p. 116 -116 from O clade to oxygen therapy p. 117 -120 from P681H mutation to pyroptosis p. 126 -131 from QazCovid-in to quaternary prevention p. 132 -132 from randomized controlled trial to Russian research organization p. 139 -139 from S clade to systemic manifestation p. 149 -152 from T lymphocyte to tyrosine kinase 2 p. 155 -160 from U.S. association to urine p. 163 -163 from V clade to VXA-CoV2-1 p. 169 -170 from waist-hip ratio to Wuhan city p. 171 -171 from Yunnan Walvax Biotechnology to Yunnan Walvax Biotechnology p. 172 -172 from zoonotic coronavirus to zoonotic virus p. 173 -173 Covid-19 Thesaurus | 4 Terminological Entries Covid-19 Thesaurus | 5 > 60 years old → over the age of 60 years 6 | Covid-19 Thesaurus 1 1 ab polyprotein → polyprotein 1ab Covid-19 Thesaurus | 7 2002 2019-nCoV infection 2 → coronavirus disease 2019 2019-new coronavirus 2002 → SARS-CoV-2 BT: date RT: SARS-CoV 2019-novel coronavirus FR: 2002 → SARS-CoV-2 URI: http://data.loterre.fr/ark:/67375/C0X-WP7M3RJ5-P 2019 coronavirus disease 2003 → coronavirus disease 2019 BT: date RT: SARS-CoV FR: 2003 2019 novel coronavirus URI: http://data.loterre.fr/ark:/67375/C0X-PZ5RND87-N → SARS-CoV-2 2003 SARS 2019 novel coronavirus disease → severe acute respiratory syndrome → coronavirus disease 2019 2004 2019 novel coronavirus infection BT: date → coronavirus disease 2019 RT: HCoV-NL63 FR: 2004 URI: http://data.loterre.fr/ark:/67375/C0X-TDXWGLQ0-3 2019 Novel (New)coronavirus → SARS-CoV-2 2005 BT: date 27e10 antigen RT: HCoV-HKU1 → calprotectin FR: 2005 URI: http://data.loterre.fr/ark:/67375/C0X-XK1480WW-J 2′-O-Mtase 2012 → non-structural protein 16 BT: date RT: MERS-CoV 2′-O-ribose-methyltransferase FR: 2012 URI: http://data.loterre.fr/ark:/67375/C0X-T085B191-J → non-structural protein 16 2019 BT: date RT: SARS-CoV-2 FR: 2019 URI: http://data.loterre.fr/ark:/67375/C0X-T8F40QV6-8 2019-nCoV → SARS-CoV-2 2019-nCoV acute respiratory disease → coronavirus disease 2019 2019-nCoV ARD → coronavirus disease 2019 2019-nCoV disease → coronavirus disease 2019 8 | Covid-19 Thesaurus 3 LNP-MRNAS 3 3'-to-5' exonuclease → non-structural protein 14 3C-like protease → non-structural protein 5 3C-like proteinase → non-structural protein 5 3CLpro → non-structural protein 5 3CL protease → non-structural protein 5 3 LNP-mRNAs Syn: BNT162b2 BT: mRNA vaccine RT: · Biopharmaceutical New Technologies · Comirnaty · Medicines and Healthcare products Regulatory Agency · Pfizer FR: 3 LNP-mRNAs URI: http://data.loterre.fr/ark:/67375/C0X-VRVTQD8N-L 3′ to 5′ endonuclease, N7-methyltransferase → non-structural protein 14 Covid-19 Thesaurus | 9 501Y.V2 5 501Y.V2 BT: new coronavirus variant RT: · E484K mutation · K417N mutation · N501Y mutation The 501.V2 variant, or simply 501.V2, is a variant of SARS-CoV-2— the virus that causes COVID-19. The variant was first detected in the Nelson Mandela Bay metropolitan area of the Eastern Cape province of South Africa and reported by the country's health department on 18 December 2020. (Wikipédia) FR: 501Y.V2 URI: http://data.loterre.fr/ark:/67375/C0X-DRTDFGBJ-L EQ: https://en.wikipedia.org/wiki/501.V2_variant https://fr.wikipedia.org/wiki/Variante_501.V2 10 | Covid-19 Thesaurus 501Y.V2 9 9-O-acetylated sialic acid → N-acetyl-9-O-acetyl neuraminic acid Covid-19 Thesaurus | 11 A222V MUTATION acute liver failure BT: systemic manifestation A Acute liver failure is the appearance of severe complications rapidly after the first signs (such as jaundice) of liver disease, and indicates that the liver has sustained severe damage (loss of function of 80–90% of A222V mutation liver cells). (Wikipedia) BT: mutation in S gene FR: insuffisance hépatique aiguë FR: mutation A222V URI: http://data.loterre.fr/ark:/67375/C0X-QPWJD408-W URI: http://data.loterre.fr/ark:/67375/C0X-TDG4S5BH-W EQ: https://en.wikipedia.org/wiki/Acute_liver_failure https://fr.wikipedia.org/wiki/Insuffisance_h %C3%A9patique_aigu%C3%AB AAK1 → adaptor-associated protein kinase 1 acute lung injury → acute pneumonia accessory protein BT: viral protein acute pneumonia NT: · protein 10 Syn: acute lung injury · protein 3a BT: pneumonia · protein 3b · protein 6 Pneumonia is an inflammatory condition of the lung affecting primarily · protein 7a the small air sacs known as alveoli. Symptoms typically include some · protein 7b combination of productive or dry cough, chest pain, fever and difficulty breathing. The severity of the condition is variable. (Wikipedia) · protein 8a · protein 8b FR: pneumonie aiguë · protein 9b URI: http://data.loterre.fr/ark:/67375/C0X-RS9TSXB4-L EQ: https://fr.wikipedia.org/wiki/Pneumonie_aigu%C3%AB FR: protéine accessoire https://en.wikipedia.org/wiki/Pneumonia URI: http://data.loterre.fr/ark:/67375/C0X-SBLZ50QV-1 ACE2 acute renal failure Syn: acute kidney injury → angiotensin converting enzyme 2 BT: systemic manifestation RT: dialysis ACE inhibitor Acute kidney injury (AKI), previously called acute renal failure (ARF), is → angiotensin-converting-enzyme inhibitor an abrupt loss of kidney function that develops within 7 days. (Wikipedia) FR: insuffisance rénale aiguë acidophil URI: http://data.loterre.fr/ark:/67375/C0X-ZG5GRGPR-X EQ: https://en.wikipedia.org/wiki/Acute_kidney_injury → eosinophil https://fr.wikipedia.org/wiki/Insuffisance_r%C3%A9nale_aigu %C3%AB ACORES-2 acute respiratory distress syndrome BT: French trial RT: · angiotensin II receptor blocker Syn: adult respiratory distress syndrome · angiotensin-converting-enzyme inhibitor BT: · lung disease FR: ACORES-2 · systemic manifestation URI: http://data.loterre.fr/ark:/67375/C0X-X3N62DJS-S RT: · cellular fibromyxoid exudate · diffuse alveolar damage · prone positioning acquired immune system Acute respiratory distress syndrome (ARDS) is a type of respiratory → adaptative immunity failure characterized by rapid onset of widespread inflammation in the lungs. Symptoms include shortness of breath, rapid breathing, and bluish skin coloration.For those who survive, a decreased quality of life acquired immunity is common. (Wikipedia) → adaptative immunity FR: syndrome de détresse respiratoire aiguë URI: http://data.loterre.fr/ark:/67375/C0X-KP4M5WK3-W EQ: https://en.wikipedia.org/wiki/ acrp30 protein Acute_respiratory_distress_syndrome → adiponectin https://fr.wikipedia.org/wiki/Syndrome_de_d %C3%A9tresse_respiratoire_aigu%C3%AB acute kidney injury → acute renal failure 12 | Covid-19 Thesaurus ADAPTOR-RELATED PROTEIN COMPLEX 2 acute respiratory failure adaptative immunity BT: systemic manifestation Syn: · acquired immune system FR: insuffisance respiratoire aiguë · acquired immunity URI: http://data.loterre.fr/ark:/67375/C0X-JH9FGN83-5 · adaptive immune response BT: immunity Ad26 NT: · adaptative immune cell · adaptative immunity function → type 26 adenovirus · cell-mediated immunity · humoral immunity Ad26.COV2.S The adaptive immune system, also referred as the acquired immune BT: adenovirus vaccine vector system, is a subsystem of the immune system that is composed of RT: · Janssen Pharmaceutica specialized, systemic cells and processes that eliminates pathogens by preventing their growth. The acquired immune system is one of the · non-replicant viral vector two main immunity strategies found in vertebrates (the other being the · type 26 adenovirus innate immune system). (Wikipedia) FR: Ad26.COV2.S URI: http://data.loterre.fr/ark:/67375/C0X-G2S0XCZH-M FR: immunité adaptative URI: http://data.loterre.fr/ark:/67375/C0X-T5PB7QGB-3 EQ: https://en.wikipedia.org/wiki/Adaptive_immune_system Ad5 https://fr.wikipedia.org/wiki/Syst %C3%A8me_immunitaire_adaptatif → type 5 adenovirus adaptative immunity function Ad5-nCoV BT: adaptative immunity Syn:
Load more

Recommended publications
  • A Guide to Buying P2, Or Equivalent, Respirators for Use in the Australian &
    Version 1.0 26 June 202022 June 2020 A Guide to Buying P2, or Equivalent, Respirators for use in the Australian & New Zealand Work Environment June 2020 – Version 1.0 Supported by Version 1.0 26 June 202022 June 2020 Contents About this document ............................................................................................................................... 1 Understanding the complex environment of Regulation and respiratory protection ............................... 2 National and International P2 standards ................................................................................................. 3 What do I need in place before I start using P2 or equivalent respirators? ............................................ 4 What should I look for when buying respirators? .................................................................................... 5 About the product(s) – An overview of P2 and equivalent respirators .................................................... 6 Identifying non-compliant products ....................................................................................................... 13 Contributing Organisations Australian Institute of Occupational Hygienists Australian Institute of Health & Safety New Zealand Occupational Hygiene Society Indoor Air Quality Association Australia Supported by Australian Council of Trade Unions SafeWork NSW SafeWork SA WorkSafe WA Health and Safety Association of NZ Primary Authors Kate Cole MAIOH Certified Occupational Hygienist (COH)® CF, Cole Health Jane
    [Show full text]
  • Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
    6/25/2020 Print - Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP Source: Vaxart, Inc. June 25, 2020 08:00 ET Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year Through Large Scale Lyophilization, Tableting and Coating SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that it signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP (AMS) affirming the parties’ intent to establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart’s oral COVID-19 vaccine. AMS will be assigning dedicated resources and equipment for the scale up and commercial production of the vaccine upon entering a formal agreement. “We believe AMS’ experience coupled with its ability to manufacture a billion or more doses per year would be a beneficial addition to our group of CDMO partners and enable the large scale manufacturing and ultimate supply of our COVID-19 vaccine for the US, Europe and other countries in need,” said Andrei Floroiu, CEO of Vaxart Inc. “We believe our oral vaccines, generated on our proven platform, have the potential to offer superior protection against airborne viruses such as SARS-CoV-2 by triggering both mucosal and systemic immunity while being administered by a room temperature-stable tablet, an enormous logistical advantage in large vaccination campaigns.” About Vaxart Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19.
    [Show full text]
  • Slowing the Spread of Infectious Diseases Using Crowdsourced Data
    Slowing the Spread of Infectious Diseases Using Crowdsourced Data March 20, 2020 By Sydney Von Arx, Isaiah Becker-Mayer, Daniel Blank, Jesse Colligan, Rhys Fenwick, Mike Hittle, Mark Ingle, Oliver Nash, Victoria Nguyen, James Petrie, Jeff Schwaber, Zsombor Szabo, Akhil Veeraghanta, Mikhail Voloshin, Tina White, Helen Xue TABLE OF CONTENTS Introduction . 2 Covid Watch Mission Statement . 2 Privacy Focus . .. 2 Current Mobile Phone Interventions . 2 Making Interventions More Efficient). 3 Proposed System: Two Parts . 4 Part 1: Bluetooth Contact Tracing . 4 Part 2: User Recommendations . 6 Why You Should Care . 6 Incentives for Health Authorities . 6 Incentives for Individuals . .. 7 Quantitative Analysis of Impact . 7 Timeline to Deployment. 8 Conclusion . 9 Who Can Help . 9 Contributors, Advisors, and Acknowledgements . 10 This white paper was last updated with minor formatting alterations on April 8, 2020 . The last alterations to its content were made on April 26, 2020 . SLOWING THE SPREAD OF INFECTIOUS DISEASES USING CROWDSOURCED DATA INTRODUCTION invasive interventions carry significant human rights costs, includ- ing the temporary loss of personal freedom and fears around Covid Watch Mission Statement whether that freedom will be restored . We are a group of volunteers — researchers, software engineers, A mobile app with a strong privacy model may also have greater privacy and public health experts — who have developed a efficacy because people will be more likely to share accurate privacy-preserving mobile app intervention to reduce the spread data if they know that data is safe . Ensuring privacy prevents of COVID-19 . Our mobile app performs automatic decentralized COVID-19 patients from being ostracized or socially harmed on contact tracing using Bluetooth proximity networks .
    [Show full text]
  • Vaccine Formulations for Protection Against Covid-19 Infection
    VACCINE FORMULATIONS FOR PROTECTION AGAINST COVID-19 INFECTION KRISTY M. AINSLIE, Professor and Vice Chair, Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina January 18, 2021 PATH TO SARS-CoV-2 PANDEMIC 2003 2012 2019 Wuhan, China, severe Before 2003 only twelve Severe acute respiratory Middle East respiratory acute respiratory animal or human syndrome coronavirus syndrome coronavirus syndrome coronavirus 2 coronaviruses were (SARS-CoV) (MERS-CoV) (SARS-CoV-2) emerged identified 8096 cases and 774 2,442 cases and 842 >78M cases and >1.7M deaths deaths deaths SARS-CoV-2 likely crossed over from bats at a wet market in Wuhan, although Pangolin’s are also likely a host. Kristy Ainslie, PhD – UNC Eshelman School of Pharmacy – Jan 18, 2021 SARS-CoV-2 BINDS THROUGH SPIKE PROTEIN TO ACE2 RBD: Receptor Binding domain NTD: N-terminal domain CTD: C-terminal domain S protein: Spike protein ACE2: Angiotensin-converting enzyme 2 - Host receptor where spike protein binds Kristy Ainslie, PhD – UNC Eshelman School of Pharmacy – Jan 18, 2021 COVID-19 IMMUNOPATHOLOGY SARS-CoV-2 infection Can include hyper-immune responses is thought to act in • A cytokine storm that leads to immune cell infiltration of the lungs part through antibody- • Alveolar damage can lead to pulmonary failure dependent • Can result in acute respiratory distress syndrome (ARDS) enhancement (ADE). Non-neutralizing antibodies formed after infection or vaccination could lead to enhanced virus uptake in cells. ADE with SARS-CoV- 2 infection has not been characterized in humans. Kristy Ainslie, PhD – UNC Eshelman School of Pharmacy – Jan 18, 2021 Image: Ulrich et al.
    [Show full text]
  • Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
    Review Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines Ekramy E. Sayedahmed 1 , Ahmed Elkashif 1, Marwa Alhashimi 1, Suryaprakash Sambhara 2,* and Suresh K. Mittal 1,* 1 Department of Comparative Pathobiology, Purdue Institute for Immunology, Inflammation and Infectious Disease, Purdue University Center for Cancer Research, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA; [email protected] (E.E.S.); [email protected] (A.E.); [email protected] (M.A.) 2 Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA * Correspondence: [email protected] (S.S.); [email protected] (S.K.M.) Received: 2 August 2020; Accepted: 17 September 2020; Published: 1 October 2020 Abstract: Ever since the discovery of vaccines, many deadly diseases have been contained worldwide, ultimately culminating in the eradication of smallpox and polio, which represented significant medical achievements in human health. However, this does not account for the threat influenza poses on public health. The currently licensed seasonal influenza vaccines primarily confer excellent strain-specific protection. In addition to the seasonal influenza viruses, the emergence and spread of avian influenza pandemic viruses such as H5N1, H7N9, H7N7, and H9N2 to humans have highlighted the urgent need to adopt a new global preparedness for an influenza pandemic. It is vital to explore new strategies for the development of effective vaccines for pandemic and seasonal influenza viruses. The new vaccine approaches should provide durable and broad protection with the capability of large-scale vaccine production within a short time. The adenoviral (Ad) vector-based vaccine platform offers a robust egg-independent production system for manufacturing large numbers of influenza vaccines inexpensively in a short timeframe.
    [Show full text]
  • Law, Technology, and Public Health in the COVID-19 Crisis
    Privacy in Pandemic: Law, Technology, and Public Health in the COVID-19 Crisis Tiffany C. Li* The COVID-19 pandemic has caused millions of deaths and disastrous consequences around the world, with lasting repercussions for every field of law, including privacy and technology. The unique characteristics of this pandemic have precipitated an increase in use of new technologies, including remote communications platforms, healthcare robots, and medical AI. Public and private actors alike are using new technologies, like heat sensing, and technologically influenced programs, like contact tracing, leading to a rise in government and corporate surveillance in sectors like healthcare, employment, education, and commerce. Advocates have raised the alarm for privacy and civil liberties violations, but the emergency nature of the pandemic has drowned out many concerns. This Article is the first comprehensive account of privacy in pandemic that maps the terrain of privacy impacts related to technology and public health responses to the COVID-19 crisis. Many have written on the general need for better health privacy protections, education privacy protections, consumer privacy protections, and protections against government and corporate surveillance. However, this Article is the first comprehensive article to examine these problems of privacy and technology specifically in light of the pandemic, arguing that the lens of the pandemic exposes the need for both wide-scale and small-scale reform of privacy law. This Article approaches these problems with a focus on technical realities and social * Visiting Clinical Assistant Professor, Boston University School of Law; Fellow, Yale Law School Information Society Project. The author thanks Tally Amir, Chinmayi Arun, Jack M.
    [Show full text]
  • Edição Atualizada Em 30/11/2020
    30 | NOVEMBRO | 2020 Edição atualizada 30 | NOVEMBRO | 2020 Edição atualizada 2020 Ministério da Saúde. Todos os direitos reservados. É permitida a reprodução parcial ou total desta obra desde que citada a fonte e que não seja para venda ou qualquer fim comercial. Venda proibida. Distribuição gratuita. Versão eletrônica disponível em: https://coronavirus.saude.gov.br/ Elaboração, distribuição e informações: MINISTÉRIO DA SAÚDE Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde Departamento de Ciência e Tecnologia Esplanada dos Ministérios, Bloco G, Ed. Sede, Sobreloja CEP: 70.058-900 – Brasília/DF Tels.: (61) 3315-7990/9227 Site: www.saude.gov.br/sctie E-mail: [email protected] Supervisão geral: Hélio Angotti Neto – Secretário de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde (SCTIE/MS) Camile Giaretta Sachetti – Diretora do Departamento de Ciência e Tecnologia (Decit/SCTIE/MS) Patrícia de Souza Boaventura - Coordenadora-Geral de Ações Estratégicas em Pesquisa Clínica (CGPCLIN/Decit/SCTIE/MS) Priscilla Azevedo Souza – Coordenadora-Geral de Ações Estratégicas em Pesquisa Clínica - Substituta (CGPCLIN/Decit/SCTIE/MS) Elaboração e organização: Evandro de Oliveira Lupatini – CGPCLIN/Decit/SCTIE/MS Felipe Fagundes Soares – CGPCLIN/Decit/SCTIE/MS Felipe Nunes Bonifácio – CGPCLIN/Decit/SCTIE/MS Glícia Pinheiro Bezerra – CGPCLIN/Decit/SCTIE/MS João Paulo Alves Oliveira – CGPCLIN/Decit/SCTIE/MS Junia Carolina Rebelo dos Santos Silva – CGPCLIN/Decit/SCTIE/MS Karla Andreia Mette Waldrich Tauil –
    [Show full text]
  • REGULATING BIOMETRICS Global Approaches and Urgent Questions
    REGULATING BIOMETRICS Global Approaches and Urgent Questions Edited by Amba Kak September 2020 REGULATING BIOMETRICS Global Approaches and Urgent Questions Edited by Amba Kak September 2020 Cite as: Amba Kak, ed., “Regulating Biometrics: Global Approaches and Urgent Questions” AI Now Institute, September 1 2020, https://ainowinstitute.org/regulatingbiometrics.html. ACKNOWLEDGMENTS I would like to acknowledge and thank Luke Strathmann for his steadfast editorial support, without which this compendium would not have come together. Thanks also to Caren Litherland for her meticulous copyediting. I’m immensely grateful to the authors of the chapters in this compendium for their seamless collaboration, despite an unexpectedly challenging year in the midst of a pandemic. I’m equally grateful, as always, to my colleagues Meredith Whittaker, Alejandro Calcaño, Theodora Dryer, Sarah Myers West, Varoon Mathur, and Inioluwa Deborah Raji for their detailed feedback and edits; and to Jason Schultz and Kate Crawford for their guidance on an earlier draft. A special thank you to Carly Kind (Ada Lovelace Institute), Ella Jakubowska (EDRi), and Vidushi Marda (Article 19) for their generous feedback on the introductory chapter. ARTWORK The images used on the cover and throughout this compendium are by Heather Dewey-Hagborg, Visiting Assistant Professor of Interactive Media at NYU Abu Dhabi and Artist Fellow at AI Now. In How Do You See Me? Dewey-Hagborg developed custom software to produce a series of images that are detected as “faces” or are recognized as her. Starting from primitive curves and gradients, images evolve to more strongly elicit the algorithmic detection and recognition response. We see the face reduced to a white circle, laying bare the racial assumptions that underpin facial detection technologies.
    [Show full text]
  • The Importance of T-Cell Responses for COVID-19 Vaccines By
    May 2021 KOL Event UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES Forward-Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “believe,” “could,” “potential,” “expect,” “will” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates; expected clinical results and trial data (including plans with respect to the proposed COVID-19 vaccine program); Vaxart’s intention to continue its efforts to advance its oral tablet seasonal flu vaccine; Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV, as well as coronaviruses such as SARS, MERS and COVID-19; and Vaxart’s expectations with regard to the vaccination market. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these
    [Show full text]
  • 2017 Annual Report
    2017 ANNUAL REPORT 1 "Implementation is simply getting things done, making an idea real. Implementation is where the advocates and journalists can sometimes turn aside, moving on to the next story or cause. The details needed for the endgame is where most ideas, policies and programs fail. Getting things done is central to this story because to achieve the systemic change necessary to eliminate the causes of worker abuse, the program had to work; its success measured by metrics of real and enduring change in the fields." - Susan Marquis Dean of the Pardee RAND Graduate School, on the Fair Food Program1 2 Photo: Shane Donglasan 3 About FFSC Program Partners Participating Buyers Mission The mission of the Fair Food Standards Council (FFSC) is to monitor the development of a sustainable agricultural industry that advances the human rights of farmworkers, the long-term interests of growers, and the ethical supply chain concerns of retail food companies through implementation of the Fair Food Program. For more information, visit fairfoodstandards.org. Board of Directors Rev. Noelle Damico - National Economic and Social Rights Initiative Dr. Patrick Mason - Department of Economics, Florida State University Cheryl Queen - Vice President of Corporate Communications, Compass Group Santiago Perez - Coalition of Immokalee Workers Nely Rodríguez - Coalition of Immokalee Workers Steven Hitov - Coalition of Immokalee Workers Executive Director Judge Laura Safer Espinoza is a recently retired New York State Supreme Court Justice who served in New York and Bronx Counties for twenty years. She was Deputy Supervising Judge for five years. Justice Safer Espinoza helped to Participating Growers design, and became the first presiding judge of, the Bronx Treatment Court, an innovative alternative to incarceration for non-violent offenders.
    [Show full text]
  • Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
    Review Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines Carlotta Biagi 1, Arianna Dondi 1,* , Sara Scarpini 1 , Alessandro Rocca 1, Silvia Vandini 2, Giulia Poletti 1 and Marcello Lanari 1 1 Pediatric Emergency Unit, Department of Medical and Surgical Sciences (DIMEC), Sant’Orsola University Hospital, 40138 Bologna, Italy; [email protected] (C.B.); [email protected] (S.S.); [email protected] (A.R.); [email protected] (G.P.); [email protected] (M.L.) 2 Pediatric and Neonatology Unit, Imola Hospital, 40026 Imola (Bologna), Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-051-2144635; Fax: +39-051-2144440 Received: 14 October 2020; Accepted: 10 November 2020; Published: 11 November 2020 Abstract: Respiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in infants and it also induces significant disease in the elderly. The clinical course may be severe, especially in high-risk populations (infants and elderly), with a large number of deaths in developing countries and of intensive care hospitalizations worldwide. To date, prevention strategies against RSV infection is based on hygienic measures and passive immunization with humanized monoclonal antibodies, limited to selected high-risk children due to their high costs. The development of a safe and effective vaccine is a global health need and an important objective of research in this field. A growing number of RSV vaccine candidates in different formats (particle-based vaccines, vector-based vaccines, subunit vaccines and live-attenuated vaccines) are being developed and are now at different stages, many of them already being in the clinical stage.
    [Show full text]
  • Europe COVID-19 Tracker Free to View Economics - Europe
    23 June 2021 Europe COVID-19 tracker Free to View Economics - Europe Falling cases, rising prices While headline case numbers are still falling on the continent, the Chris Hare Senior Economist Delta variant is on the rise… HSBC Bank plc …which could risk reopening delays but is unlikely to scupper the recovery, given vaccines and business confidence Supply-demand imbalances could be lifting inflation but, in the eurozone at least, most pressures should prove temporary Delta dominance COVID-19 case numbers continue to fall across most of the continent (Chart 1), as does intensive care occupancy (Chart 2), while the vaccine rollout continues at a rapid pace (Chart 3). And countries are continuing along their reopening roadmaps. In Germany, case levels are now low enough to allow for the resumption of indoor restaurant dining, nightclubs in Catalonia reopened on 21 June (albeit with a 3.30am curfew) and from 28 June, outdoor mask wearing will no longer be required in Italy. There are rising concerns, however, about the spread of the Delta variant. It may now account for almost all new cases in the UK and Portugal and around a quarter in Italy (Chart 5). The European Centre for Disease Control has estimated that the variant will account for 90% of European cases by the end of August (AFP, 23 June). The big question is whether this risks plans for further reopening. The UK, where cases are rising sharply, is a litmus test. While hospitalisations remain low (Chart 7), the spread of the variant was enough to delay a further easing from 21 June to 19 July in England.
    [Show full text]